You are here: Industry Insights > approval

News List

Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
April 28, 2025
This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
Drug Marketing in China and Worldwide (August)(2023) PharmaSources
September 01, 2023
The official website shows that the drugs developed by major companies have been declared for marketing.
A Review of Oncology Biosimilars Products and Companies David Orchard-Webb
May 12, 2022
Biologics and biosimilars are large and generally complex therapeutics produced from living organisms.
Pharmaceutical News of the Week (June.22-27) | PharmaSources.com PharmaSources/Caicai
July 01, 2020
With the last week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 22-28, including 22 pieces.
Pharmaceutical News of the Week （June.15th-19th）| PharmaSources.com PharmaSources/Caicai
June 23, 2020
With the third week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 15-19.
Pharmaceutical News of the Week June 8th-12th | PharmaSources.com PharmaSources/Caicai
June 22, 2020
With the second week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 8-12.
Pharmaceutical News of the Week (June 5th) | PharmaSources.com PharmaSources/Caicai
June 11, 2020
With the first week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved approval, R&D, policies, transactions, and marketing that happened during June 1-5, including 21 pieces.
Illuccix? Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America PR Newswire
March 18, 2025
Telix announces that the ANVISA has approved Illuccix? the Company's lead prostate cancer imaging agent.
Illuccix? Approved in the United Kingdom PR Newswire
February 13, 2025
Telix today Announces that UK Medicines and MHRA has Approved the MAA for its prostate cancer medicine.
Glenmark announces approval for Ryaltris in Australia biospectrumasia
December 22, 2019
Glenmark Pharmaceuticals has announced that Seqirus Pty. Ltd. (Seqirus) has received marketing approval for Ryaltris? from the Therapeutic Goods Administration (TGA), Australia. This paves the way for the launch of Ryaltris? in Australia through the partn